Related references
Note: Only part of the references are listed.Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial
Corinne Faivre-Finn et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients
Jacky Chow et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
Daniel R. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma et al.
LANCET (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L. Topalian et al.
JAMA ONCOLOGY (2019)
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
Willemijn S. M. E. Theelen et al.
JAMA ONCOLOGY (2019)
Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer
Kazue Yoneda et al.
BRITISH JOURNAL OF CANCER (2019)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy
William L. Hwang et al.
JAMA ONCOLOGY (2018)
A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Anurag K. Singh et al.
CLINICAL CANCER RESEARCH (2017)